
    
      This study, in subjects with FGIDs, is a , randomized, sham-controlled, single-centre pilot
      investigation designed to compare two parallel groups, gammaCoreÂ®-G (active treatment) and a
      sham, (inactive) treatment. The study period will begin with a two-week run-in period,
      followed by a four week comparative period when the subjects will randomized (1:1) to either
      active treatment or sham (inactive) treatment. The comparative period will be followed by an
      open label four week period, where the subjects in the sham treatment group will switch in
      treatment assignment to receive active treatment and the active group will continue to
      receive an active treatment.
    
  